Home » Healthcare » Asia Pacific Human Insulin Market

Asia Pacific Human Insulin Market

Asia Pacific Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Asia Pacific Human Insulin Market Size 2023	USD 6,171.90 Million
Asia Pacific Human Insulin Market, CAGR	5.70%
Asia Pacific Human Insulin Market Size 2032	USD 10,169.13 Million

Market Overview

Asia Pacific Human Insulin market size was valued at USD 6,171.90 million in 2023 and is anticipated to reach USD 10,169.13 million by 2032, at a CAGR of 5.70% during the forecast period (2023-2032).

The Asia Pacific human insulin market is experiencing steady growth, driven by the rising prevalence of diabetes, particularly type 2 diabetes, across densely populated countries such as China and India. Increasing awareness of early diagnosis and insulin therapy, coupled with government initiatives aimed at improving diabetes management, continues to bolster market expansion. The growing elderly population and shifting lifestyles marked by poor dietary habits and reduced physical activity further contribute to the surge in insulin demand. Additionally, advancements in insulin delivery devices, such as insulin pens and pumps, are enhancing patient compliance and treatment outcomes. The expansion of healthcare infrastructure, especially in emerging economies, and the increasing affordability and availability of biosimilar insulin products are further shaping market trends. Strategic collaborations among pharmaceutical companies and the introduction of innovative, cost-effective therapies are also playing a key role in sustaining growth across the region.

The Asia Pacific human insulin market demonstrates significant geographical diversity, with major growth concentrated in countries such as China, India, Japan, and South Korea, while emerging economies like Indonesia, Vietnam, and the Philippines are witnessing increasing adoption due to improving healthcare infrastructure and rising diabetes awareness. Urbanization, changing lifestyles, and government initiatives across the region are fueling the demand for effective insulin therapies. Key players driving the market forward include global pharmaceutical giants such as Novo Nordisk A/S, Eli Lilly and Company, and Pfizer, alongside strong regional contributors like Biocon, Wockhardt, Tonghua Dongbao Pharmaceutical Co., and Lupin. These companies are focusing on expanding product portfolios, enhancing distribution networks, and launching affordable biosimilars to cater to a wide patient base. Strategic collaborations, R&D investments, and innovations in insulin delivery technologies continue to strengthen their market positions and support the evolving needs of diabetic populations across the Asia Pacific region.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Asia Pacific human insulin market was valued at USD 6,171.90 million in 2023 and is projected to reach USD 10,169.13 million by 2032, growing at a CAGR of 5.70%.

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
Increasing diabetes prevalence across the region, particularly in countries like China and India, is driving significant demand for insulin products.

The market is witnessing a shift toward biosimilars, providing more affordable insulin options and expanding patient access.
Technological advancements in insulin delivery devices, such as insulin pens and pumps, are enhancing patient compliance and convenience.
Strong competition exists among global giants like Novo Nordisk, Eli Lilly, and regional players like Biocon and Lupin.
Market restraints include the high cost of insulin therapies and limited access in rural areas, hindering overall growth potential.
Regional differences show robust growth in China, India, and Japan, while emerging markets in Southeast Asia continue to expand access to insulin.

Report Scope

This report segments the Asia Pacific Human Insulin Market as follows:

Market Drivers

Rising Diabetes Prevalence and Aging Population

One of the primary drivers of the Asia Pacific human insulin market is the escalating prevalence of diabetes, particularly type 2 diabetes, across the region. For instance, the International Diabetes Federation estimates that Asia is home to over half of the global diabetic population. Countries like China, India, and Indonesia are witnessing a significant increase in diabetes incidence due to rapid urbanization, sedentary lifestyles, and unhealthy dietary patterns. This surge in diabetic patients has created a substantial and growing demand for effective glucose management therapies, including human insulin. Additionally, the region’s aging population contributes to the increasing diabetes burden, as age is a significant risk factor for the development of insulin resistance and type 2 diabetes.

Government Initiatives and Healthcare Policy Support

Governmental efforts and healthcare policy reforms are playing a pivotal role in shaping the human insulin market in Asia Pacific. For instance, several countries have introduced national diabetes programs focused on improving early diagnosis, patient education, and access to affordable treatment options. Subsidies for insulin and other diabetes medications, combined with public health awareness campaigns, have significantly improved insulin accessibility in rural and underdeveloped areas. Moreover, partnerships between public health agencies and private pharmaceutical firms are fostering innovation and increasing the availability of both branded and biosimilar human insulin products. These supportive policies are creating an enabling environment for market growth across urban and semi-urban areas.

Advancements in Insulin Delivery Technology

Technological innovation is another major catalyst propelling the Asia Pacific human insulin market forward. Traditional vial-and-syringe methods are gradually being replaced by more user-friendly delivery devices such as insulin pens and insulin pumps. These devices enhance treatment adherence by offering more convenient, precise, and painless delivery of insulin, especially beneficial for the elderly and pediatric populations. In addition, the integration of smart technologies—such as Bluetooth-enabled insulin pens and glucose monitoring systems—is improving patient compliance and enabling real-time data sharing with healthcare providers. These advancements not only increase patient satisfaction but also contribute to better clinical outcomes, thereby boosting the overall demand for human insulin therapies.

Rising Penetration of Biosimilars and Private Sector Engagement

The growing presence of biosimilar human insulin products in the Asia Pacific market is making insulin therapy more affordable and accessible. Several regional pharmaceutical companies are actively investing in the development and commercialization of biosimilars to cater to the rising demand and reduce dependency on imported brands. These efforts are supported by favorable regulatory frameworks that expedite biosimilar approvals while maintaining stringent quality standards. Furthermore, the private sector’s increased involvement, through investments, strategic collaborations, and product launches, is expanding the competitive landscape and driving innovation. The resultant market dynamism is creating more choices for patients and healthcare providers, ultimately accelerating the adoption of human insulin across diverse socioeconomic segments.

Market Trends

Surge in Demand for Biosimilar Insulin Products

A notable trend in the Asia Pacific human insulin market is the growing adoption of biosimilar insulin products. With rising healthcare costs and increasing demand for cost-effective treatment options, biosimilars are gaining traction among both healthcare providers and patients. Several local and regional pharmaceutical companies have entered the market, offering competitively priced alternatives to branded insulin products. These biosimilars maintain comparable efficacy and safety profiles, making them attractive for national health systems seeking to expand access to insulin therapy. Regulatory frameworks in countries such as India, China, and South Korea are evolving to support the development and faster approval of biosimilars, further accelerating their integration into mainstream diabetes care.

Technological Advancements in Insulin Delivery Systems

The Asia Pacific market is witnessing significant technological progress in insulin delivery systems, transforming the patient experience and improving adherence to treatment. For instance, Medtronic has solidified its dominance in the Asia Pacific market by continuously innovating and enhancing its technology for insulin users. Traditional insulin administration methods are being replaced by more sophisticated solutions such as prefilled insulin pens, insulin pumps, and smart injection devices. These innovations offer greater accuracy, ease of use, and convenience, particularly for the elderly and children who require simpler dosing mechanisms. The integration of digital health technologies, including mobile apps and Bluetooth-enabled insulin pens, allows real-time monitoring and personalized dosing recommendations. This convergence of medical devices and digital platforms is fostering a more patient-centric approach, which is expected to gain momentum in the coming years.

Increased Focus on Preventive Healthcare and Early Diagnosis

Preventive healthcare and early diagnosis of diabetes are becoming central to national health strategies across Asia Pacific. For instance, the International Diabetes Federation (IDF) reports that there are roughly 537 million diabetes patients aged between 20 and 79 years, with projections indicating a significant increase by 2045. Governments and non-profit organizations are launching large-scale screening programs, awareness campaigns, and community outreach initiatives to promote early detection and better management of diabetes. As a result, more individuals are being diagnosed at earlier stages, leading to an uptick in the initiation of insulin therapy. This trend is also prompting pharmaceutical companies to expand their market reach into semi-urban and rural areas, where awareness and access have historically been limited. Early diagnosis combined with timely intervention is driving sustained demand for human insulin.

Expanding Role of Local Manufacturers and Strategic Collaborations

Local manufacturers are playing an increasingly influential role in shaping the Asia Pacific human insulin market. These companies are not only addressing affordability challenges but also contributing to regional self-sufficiency in insulin production. Strategic partnerships between local and global firms are becoming more common, aiming to co-develop innovative insulin formulations and improve distribution networks. Collaborative efforts between industry stakeholders, research institutions, and healthcare providers are also facilitating technology transfer and product localization. This regionalization of production and distribution is expected to enhance supply chain resilience and meet the growing demand more efficiently.

Market Challenges Analysis

High Cost of Insulin Therapy and Limited Access in Rural Areas

Despite growing demand and government efforts, the high cost of insulin therapy remains a significant barrier for many patients across the Asia Pacific region. For instance, research indicates that more than half of those who need insulin globally still cannot afford or access it due to high costs. Branded insulin products, especially analog variants, are often priced beyond the reach of low-income populations. Even though biosimilars offer a more affordable alternative, their market penetration is still limited in several countries due to regulatory hurdles and lack of awareness. In rural and remote areas, access to consistent insulin supply, refrigeration for storage, and trained healthcare professionals is often inadequate. These infrastructural and economic challenges hinder the timely initiation and continuation of insulin therapy, especially among underserved populations, ultimately affecting diabetes outcomes.

Regulatory Complexities and Supply Chain Disruptions

The Asia Pacific human insulin market also faces challenges stemming from complex and inconsistent regulatory environments across different countries. Varying standards for product approval, clinical trials, and biosimilar equivalency create difficulties for manufacturers looking to expand across borders. These inconsistencies not only delay market entry but also increase development and compliance costs. Moreover, disruptions in global and regional supply chains—exacerbated by geopolitical tensions, pandemics, and logistics inefficiencies—have highlighted the vulnerability of insulin distribution systems. Interruptions in raw material supply and manufacturing operations can result in insulin shortages, adversely impacting patient care. Addressing these regulatory and logistical hurdles is essential for ensuring a stable, equitable, and scalable insulin supply across the region.

Market Opportunities

The Asia Pacific human insulin market presents substantial opportunities driven by the rapid expansion of healthcare infrastructure and growing investments in chronic disease management. Emerging economies such as India, China, Vietnam, and the Philippines are witnessing increased healthcare spending, both from government and private sectors, enabling broader access to insulin therapies. Urbanization, coupled with a rise in lifestyle-related diseases, has led to a larger diabetic population that demands sustained and effective treatment solutions. As awareness around diabetes prevention and treatment grows, there is an increasing inclination toward early diagnosis and proactive disease management, fostering long-term demand for human insulin. Additionally, the continued rollout of universal healthcare schemes and subsidized drug programs across several countries is expanding patient reach and creating favorable conditions for insulin manufacturers.

Another key opportunity lies in the development and adoption of innovative delivery systems and digital health technologies tailored to the needs of local populations. Smart insulin pens, wearable devices, and mobile-based diabetes management platforms are opening new avenues for personalized, efficient treatment solutions that can significantly enhance patient adherence and clinical outcomes. Moreover, the production and commercialization of biosimilar insulin products by regional pharmaceutical companies offer a scalable solution to affordability concerns while reducing dependency on imports. This creates an attractive environment for foreign direct investments and strategic collaborations aimed at technology transfer and market expansion. As regulatory frameworks across the region continue to mature and align with international standards, they are expected to facilitate faster approval and market entry of next-generation insulin products, positioning Asia Pacific as a key growth engine in the global insulin market.

Market Segmentation Analysis:

By Device:

Pens
Syringes
Others

By Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

China
Japan
South Korea
India
Australia
Thailand
Indonesia
Vietnam
Malaysia
Philippines
Taiwan
Rest of Asia Pacific

Regional Analysis

China

China, accounting for the largest share of the Asia Pacific human insulin market at approximately 30%, remains the dominant regional player due to its massive diabetic population and continued government investment in healthcare infrastructure. The country has seen increased awareness around diabetes management, supported by extensive public health campaigns and national screening programs. Local production of biosimilar insulin has also accelerated, reducing costs and increasing accessibility, especially in second- and third-tier cities. China’s ongoing reforms in healthcare reimbursement and drug procurement are improving patient access to both traditional and analog insulin types. As urbanization and sedentary lifestyles continue to contribute to rising diabetes prevalence, China’s demand for insulin is expected to maintain a strong upward trajectory.

India

India follows closely, capturing around 18% of the regional market. The country’s growing middle class, increasing diabetes prevalence, and improvements in diagnostic infrastructure are fueling market expansion. While human insulin dominates the public health sector due to affordability, insulin analogs are gradually gaining traction in private healthcare settings. The government’s efforts to subsidize diabetes care through programs like Ayushman Bharat are broadening access to essential treatments. Furthermore, India’s strong pharmaceutical manufacturing base enables domestic production of cost-effective biosimilar insulin, which is widely distributed both locally and to other developing markets. The combination of policy support, patient outreach, and private sector innovation positions India as a rapidly growing insulin market within the region.

Japan and South Korea

Japan and South Korea, together, contribute around 22% of the regional market share. Both countries have highly developed healthcare systems and high per capita healthcare expenditure, leading to widespread adoption of advanced insulin analogs and innovative delivery technologies like insulin pens and pumps. Japan’s aging population, coupled with a well-established reimbursement framework, has created a mature insulin market focused on therapeutic efficiency and convenience. Similarly, South Korea benefits from strong regulatory support, high awareness, and government programs that emphasize disease prevention and management, making it a key growth center for premium insulin products.

Rest of Asia Pacific

The Rest of Asia Pacific, including Australia, Thailand, Indonesia, Vietnam, Malaysia, the Philippines, and Taiwan, accounts for the remaining 30% of the market. While market maturity varies across these countries, common growth drivers include increasing diabetes incidence, improved healthcare access, and rising investments in public health initiatives. Australia, with its robust healthcare policies, is leaning toward high-end insulin therapies, whereas Southeast Asian nations are focusing on affordability and access. Multinational companies are expanding their footprint in these emerging markets through partnerships and biosimilar launches, supporting long-term growth potential across the broader Asia Pacific region.

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co.
Eli Lilly and Company

Competitive Analysis

The Asia Pacific human insulin market is highly competitive, with key players vying for dominance in both developed and emerging economies. Leading global players such as Novo Nordisk A/S, Eli Lilly and Company, and Pfizer continue to hold substantial market share due to their strong brand recognition, extensive distribution networks, and wide product portfolios. These companies are focusing on expanding their insulin offerings with both traditional human insulin and innovative analogs to meet the growing demand for diabetes management solutions across the region. These companies continue to invest heavily in research and development to bring innovative insulin formulations and delivery systems to market, catering to the diverse needs of diabetic patients across the region. In addition to multinational companies, regional players are gaining traction by focusing on cost-effective solutions, such as biosimilar and generic insulin products. These players leverage local manufacturing capabilities and strong distribution channels to offer more affordable alternatives, making insulin therapies more accessible to a wider population. Strategic collaborations, partnerships, and acquisitions are common in the market, enabling both global and local firms to expand their reach and enhance their product offerings. Furthermore, advancements in insulin delivery technologies, such as prefilled insulin pens and smart insulin pumps, are playing a crucial role in differentiating products and driving patient adherence. The competitive landscape is also influenced by regulatory environments, pricing pressures, and shifting consumer preferences, as healthcare systems across the region prioritize cost-effective diabetes management solutions. This dynamic environment requires players to continuously innovate and adapt to meet the evolving demands of the Asia Pacific market.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The Asia Pacific human insulin market is moderately concentrated, with a few dominant global players and numerous regional competitors shaping its landscape. Major companies like Novo Nordisk, Eli Lilly, and Pfizer control a significant share of the market due to their established product portfolios, strong brand presence, and extensive distribution networks. These industry leaders focus on both branded insulin and biosimilar products to cater to a broad range of consumers. However, the market also features regional players such as Biocon, Lupin, and Tonghua Dongbao Pharmaceutical Co., which have been able to capitalize on the demand for cost-effective insulin therapies, especially in emerging markets. The market is characterized by a strong focus on innovation in insulin delivery systems, including prefilled pens and insulin pumps, as well as a growing shift toward biosimilars to increase affordability. Regulatory support, strategic collaborations, and local production capacity continue to play crucial roles in determining market dynamics.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The demand for human insulin in Asia Pacific will continue to rise due to the increasing prevalence of diabetes and an aging population.
Government initiatives aimed at improving diabetes care and affordability will expand access to insulin therapies, especially in underserved areas.
The adoption of biosimilar insulin products will grow as they provide more affordable alternatives to branded insulin, addressing cost concerns.
Technological advancements in insulin delivery devices, such as smart pens and pumps, will enhance patient compliance and treatment efficiency.
Growing healthcare infrastructure in emerging markets will drive insulin demand, with improvements in diagnostics and treatment accessibility.
The rising focus on preventive healthcare will contribute to early diabetes detection and early-stage insulin therapy initiation.
Increased competition among global and regional insulin manufacturers will lead to greater product diversification and improved therapeutic options.
The development and commercialization of long-acting insulin formulations and combination therapies will offer more effective and convenient treatment options.
Expanding partnerships between multinational pharmaceutical companies and local manufacturers will enhance supply chains and expand market reach.
Regulatory frameworks across the region will continue to evolve, ensuring faster approval processes for new insulin products and improving overall market stability.

CHAPTER NO. 1 : INTRODUCTION 24
1.1.1. Report Description 24
Purpose of the Report 24
USP & Key Offerings 24
1.1.2. Key Benefits for Stakeholders 24
1.1.3. Target Audience 25
1.1.4. Report Scope 25
1.1.5. Regional Scope 26
CHAPTER NO. 2 : EXECUTIVE SUMMARY 27
2.1. Human Insulin Market Snapshot 27
2.1.1. Asia Pacific Human Insulin Market, 2018 – 2032 (USD Million) 28
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 29
3.1. Russia-Ukraine and Israel-Palestine War Impacts 29
CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 30
4.1. Introduction 30
4.2. Market Drivers 31
4.2.1. Driving Factor 1 Analysis 31
4.2.2. Driving Factor 2 Analysis 32
4.3. Market Restraints 33
4.3.1. Restraining Factor Analysis 33
4.4. Market Opportunities 34
4.4.1. Market Opportunity Analysis 34
4.5. Porter’s Five Forces Analysis 35
4.6. Value Chain Analysis 36
4.7. Buying Criteria 37
CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 38
5.1. Import Analysis by Region 38
5.1.1. Asia Pacific Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 38
5.2. Export Analysis by Region 39
5.2.1. Asia Pacific Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 39
CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 40
6.1. Demand Analysis by Region 40
6.1.1. Asia Pacific Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 40
6.2. Supply Analysis by Region 41
6.2.1. Asia Pacific Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 41
CHAPTER NO. 7 : PRODUCTION ANALYSIS 42
7.1. Production Analysis by Region 42
7.1.1. Asia Pacific Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 42
CHAPTER NO. 8 : PRICE ANALYSIS 43
8.1. Price Analysis by Region 43
8.1.1. Asia Pacific Human Insulin Market Price, By Region, 2018 – 2023 43
8.1.2. Asia Pacific Device Market Price, By Region, 2018 – 2023 43
8.2. Price Analysis by Device 44
8.2.1. Asia Pacific Human Insulin Market Price, By Device, 2018 – 2023 44
8.2.2. Asia Pacific Device Market Price, By Device, 2018 – 2023 44
CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 45
9.1. Key Raw Materials and Suppliers 45
9.2. Key Raw Materials Price Trend 45
CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 46
10.1. Manufacturing Cost Analysis 46
10.2. Manufacturing Process 46
CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 47
11.1. Company Market Share Analysis – 2023 47
11.1.1. Asia Pacific Human Insulin Market: Company Market Share, by Volume, 2023 47
11.1.2. Asia Pacific Human Insulin Market: Company Market Share, by Revenue, 2023 48
11.1.3. Asia Pacific Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 48
11.1.4. Asia Pacific Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 49
11.2. Asia Pacific Human Insulin Market Company Volume Market Share, 2023 50
11.3. Asia Pacific Human Insulin Market Company Revenue Market Share, 2023 51
11.4. Company Assessment Metrics, 2023 52
11.4.1. Stars 52
11.4.2. Emerging Leaders 52
11.4.3. Pervasive Players 52
11.4.4. Participants 52
11.5. Start-ups /SMEs Assessment Metrics, 2023 52
11.5.1. Progressive Companies 52
11.5.2. Responsive Companies 52
11.5.3. Dynamic Companies 52
11.5.4. Starting Blocks 52
11.6. Strategic Developments 53
11.6.1. Acquisitions & Mergers 53
New Product Launch 53
Regional Expansion 53
11.7. Key Players Product Matrix 54
CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 55
12.1. PESTEL 55
12.1.1. Political Factors 55
12.1.2. Economic Factors 55
12.1.3. Social Factors 55
12.1.4. Technological Factors 55
12.1.5. Environmental Factors 55
12.1.6. Legal Factors 55
12.2. Adjacent Market Analysis 55
CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY DEVICE SEGMENT ANALYSIS 56
13.1. Human Insulin Market Overview, by Device Segment 56
13.1.1. Human Insulin Market Revenue Share, By Device, 2023 & 2032 57
13.1.2. Human Insulin Market Attractiveness Analysis, By Device 58
13.1.3. Incremental Revenue Growth Opportunity, by Device, 2024 – 2032 58
13.1.4. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 59
13.2. Pens 60
13.2.1. Asia Pacific Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61
13.2.2. Asia Pacific Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61
13.3. Syringes 62
13.3.1. Asia Pacific Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63
13.3.2. Asia Pacific Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63
13.4. Others 64
13.4.1. Asia Pacific Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65
13.4.2. Asia Pacific Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65
13.5. Device 4 66
13.5.1. Asia Pacific Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67
13.5.2. Asia Pacific Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67
13.6. Device 5 68
13.6.1. Asia Pacific Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69
13.6.2. Asia Pacific Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69
CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY INDICATION SEGMENT ANALYSIS 70
14.1. Human Insulin Market Overview, by Indication Segment 70
14.1.1. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 71
14.1.2. Human Insulin Market Attractiveness Analysis, By Indication 72
14.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 72
14.1.4. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 73
14.2. Type 1 Diabetes 74
14.2.1. Asia Pacific Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75
14.2.2. Asia Pacific Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75
14.3. Type 2 Diabetes 76
14.3.1. Asia Pacific Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77
14.3.2. Asia Pacific Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77
14.4. Gestational Diabetes 78
14.4.1. Asia Pacific Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79
14.4.2. Asia Pacific Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79
14.5. Indication 4 80
14.5.1. Asia Pacific Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81
14.5.2. Asia Pacific Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81
14.6. Indication 5 82
14.6.1. Asia Pacific Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83
14.6.2. Asia Pacific Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83
CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY INSULIN SEGMENT ANALYSIS 84
15.1. Human Insulin Market Overview, by Insulin Segment 84
15.1.1. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 85
15.1.2. Human Insulin Market Attractiveness Analysis, By Insulin 86
15.1.3. Incremental Revenue Growth Opportunity, by Insulin, 2024 – 2032 86
15.1.4. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 87
15.2. Rapid-acting insulin 88
15.2.1. Asia Pacific Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89
15.2.2. Asia Pacific Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89
15.3. Short-acting insulin 90
15.3.1. Asia Pacific Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91
15.3.2. Asia Pacific Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91
15.4. Intermediate-acting insulin 92
15.4.1. Asia Pacific Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93
15.4.2. Asia Pacific Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93
15.5. Others 94
15.5.1. Asia Pacific Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95
15.5.2. Asia Pacific Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95
15.6. Insulin 5 96
15.6.1. Asia Pacific Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97
15.6.2. Asia Pacific Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97
CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 98
16.1. Human Insulin Market Overview, by Technology Segment 98
16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 99
16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 100
16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 100
16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 101
16.2. Technology 1 102
16.2.1. Asia Pacific Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103
16.2.2. Asia Pacific Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103
16.3. Technology 2 104
16.3.1. Asia Pacific Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105
16.3.2. Asia Pacific Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105
16.4. Technology 3 106
16.4.1. Asia Pacific Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107
16.4.2. Asia Pacific Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107
16.5. Technology 4 108
16.5.1. Asia Pacific Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109
16.5.2. Asia Pacific Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109
16.6. Technology 5 110
16.6.1. Asia Pacific Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111
16.6.2. Asia Pacific Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111
CHAPTER NO. 17 : HUMAN INSULIN MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 112
17.1. Human Insulin Market Overview, by Distribution Channel Segment 112
17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 113
17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 114
17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 114
17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 115
17.2. Hospital Pharmacies 116
17.2.1. Asia Pacific Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117
17.2.2. Asia Pacific Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117
17.3. Drug Stores and Retail Pharmacies 118
17.3.1. Asia Pacific Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119
17.3.2. Asia Pacific Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119
17.4. Online Providers 120
17.4.1. Asia Pacific Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121
17.4.2. Asia Pacific Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121
17.5. Distribution Channel 4 122
17.5.1. Asia Pacific Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123
17.5.2. Asia Pacific Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123
17.6. Distribution Channel 5 124
17.6.1. Asia Pacific Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125
17.6.2. Asia Pacific Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125
CHAPTER NO. 18 : HUMAN INSULIN MARKET – REGIONAL ANALYSIS 126
18.1. Human Insulin Market Overview, by Regional Segments 126
18.2. Region 127
18.2.1. Asia Pacific Human Insulin Market Revenue Share, By Region, 2023 & 2032 127
18.2.2. Human Insulin Market Attractiveness Analysis, By Region 128
18.2.3. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 128
18.2.4. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 129
18.2.5. Asia Pacific Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130
18.2.6. Asia Pacific Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130
18.3. Device 131
18.3.1. Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131
18.4. Asia Pacific Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131
18.5. Indication 132
18.5.1. Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132
18.5.2. Asia Pacific Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132
18.6. Insulin 133
18.6.1. Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133
18.6.2. Asia Pacific Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133
18.7. Technology 134
18.7.1. Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134
18.7.2. Asia Pacific Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134
18.8. Distribution Channel 135
18.8.1. Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135
18.8.2. Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135
CHAPTER NO. 19 : HUMAN INSULIN MARKET – NORTH AMERICA 136
19.1. North America 136
19.1.1. Key Highlights 136
19.1.2. North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137
19.1.3. North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138
19.1.4. North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139
19.1.5. North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140
19.1.6. North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141
19.1.7. North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142
19.2. U.S. 143
19.3. Canada 143
19.4. Mexico 143
CHAPTER NO. 20 : HUMAN INSULIN MARKET – EUROPE 144
20.1. Europe 144
20.1.1. Key Highlights 144
20.1.2. Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145
20.1.3. Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146
20.1.4. Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147
20.1.5. Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148
20.1.6. Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149
20.1.7. Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150
20.2. UK 151
20.3. France 151
20.4. Germany 151
20.5. Italy 151
20.6. Spain 151
20.7. Russia 151
20.8. Belgium 151
20.9. Netherland 151
20.10. Austria 151
20.11. Sweden 151
20.12. Poland 151
20.13. Denmark 151
20.14. Switzerland 151
20.15. Rest of Europe 151
CHAPTER NO. 21 : HUMAN INSULIN MARKET – ASIA PACIFIC 152
21.1. Asia Pacific 152
21.1.1. Key Highlights 152
21.1.2. Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153
21.1.3. Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154
21.1.4. Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155
21.1.5. Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156
21.1.6. Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157
21.1.7. Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158
21.2. China 159
21.3. Japan 159
21.4. South Korea 159
21.5. India 159
21.6. Australia 159
21.7. Thailand 159
21.8. Indonesia 159
21.9. Vietnam 159
21.10. Malaysia 159
21.11. Philippines 159
21.12. Taiwan 159
21.13. Rest of Asia Pacific 159
CHAPTER NO. 22 : HUMAN INSULIN MARKET – LATIN AMERICA 160
22.1. Latin America 160
22.1.1. Key Highlights 160
22.1.2. Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161
22.1.3. Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162
22.1.4. Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163
22.1.5. Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164
22.1.6. Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165
22.1.7. Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166
22.2. Brazil 167
22.3. Argentina 167
22.4. Peru 167
22.5. Chile 167
22.6. Colombia 167
22.7. Rest of Latin America 167
CHAPTER NO. 23 : HUMAN INSULIN MARKET – MIDDLE EAST 168
23.1. Middle East 168
23.1.1. Key Highlights 168
23.1.2. Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169
23.1.3. Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170
23.1.4. Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171
23.1.5. Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172
23.1.6. Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173
23.1.7. Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174
23.2. UAE 175
23.3. KSA 175
23.4. Israel 175
23.5. Turkey 175
23.6. Iran 175
23.7. Rest of Middle East 175
CHAPTER NO. 24 : HUMAN INSULIN MARKET – AFRICA 176
24.1. Africa 176
24.1.1. Key Highlights 176
24.1.2. Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177
24.1.3. Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178
24.1.4. Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179
24.1.5. Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180
24.1.6. Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181
24.1.7. Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182
24.2. Egypt 183
24.3. Nigeria 183
24.4. Algeria 183
24.5. Morocco 183
24.6. Rest of Africa 183
CHAPTER NO. 25 : COMPANY PROFILES 184
25.1. Novo Nordisk A/S 184
25.1.1. Company Overview 184
25.1.2. Product Portfolio 184
25.1.3. Swot Analysis 184
25.1.4. Business Strategy 185
25.1.5. Financial Overview 185
25.1.6. MannKind Corporation 186
25.1.7. Pfizer 186
25.1.8. Wockhardt 186
25.1.9. Biocon 186
25.1.10. Lupin 186
25.1.11. Tonghua Dongbao Pharmaceutical Co 186
25.1.12. Eli Lilly and Company 186
25.1.13. Company 9 186
25.1.14. Company 10 186
25.1.15. Company 11 186
25.1.16. Company 12 186
25.1.17. Company 13 186
25.1.18. Company 14 186
CHAPTER NO. 26 : RESEARCH METHODOLOGY 187
26.1. Research Methodology 187
26.1.1. Phase I – Secondary Research 188
26.1.2. Phase II – Data Modeling 188
Company Share Analysis Model 189
Revenue Based Modeling 189
26.1.3. Phase III – Primary Research 190
26.1.4. Research Limitations 191
Assumptions 191

List of Figures
FIG NO. 1. Asia Pacific Human Insulin Market Revenue, 2018 – 2032 (USD Million) 30
FIG NO. 2. Porter’s Five Forces Analysis for Asia Pacific Human Insulin Market 37
FIG NO. 3. Value Chain Analysis for Asia Pacific Human Insulin Market 38
FIG NO. 4. Asia Pacific Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 40
FIG NO. 5. Asia Pacific Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 41
FIG NO. 6. Asia Pacific Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 42
FIG NO. 7. Asia Pacific Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 43
FIG NO. 8. Asia Pacific Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 44
FIG NO. 9. Asia Pacific Human Insulin Market Price, By Region, 2018 – 2023 45
FIG NO. 10. Asia Pacific Human Insulin Market Price, By Device, 2018 – 2023 46
FIG NO. 11. Raw Materials Price Trend Analysis, 2018 – 2023 47
FIG NO. 12. Manufacturing Cost Analysis 48
FIG NO. 13. Manufacturing Process 48
FIG NO. 14. Company Share Analysis, 2023 49
FIG NO. 15. Company Share Analysis, 2023 50
FIG NO. 16. Company Share Analysis, 2023 50
FIG NO. 17. Company Share Analysis, 2023 51
FIG NO. 18. Human Insulin Market – Company Volume Market Share, 2023 52
FIG NO. 19. Human Insulin Market – Company Revenue Market Share, 2023 53
FIG NO. 20. Human Insulin Market Revenue Share, By Device, 2023 & 2032 59
FIG NO. 21. Market Attractiveness Analysis, By Device 60
FIG NO. 22. Incremental Revenue Growth Opportunity by Device, 2024 – 2032 60
FIG NO. 23. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 61
FIG NO. 24. Asia Pacific Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 62
FIG NO. 25. Asia Pacific Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 64
FIG NO. 26. Asia Pacific Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 66
FIG NO. 27. Asia Pacific Human Insulin Market for Device 4, Revenue (USD Million) 2018 – 2032 68
FIG NO. 28. Asia Pacific Human Insulin Market for Device 5, Revenue (USD Million) 2018 – 2032 70
FIG NO. 29. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 73
FIG NO. 30. Market Attractiveness Analysis, By Indication 74
FIG NO. 31. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 74
FIG NO. 32. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 75
FIG NO. 33. Asia Pacific Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 76
FIG NO. 34. Asia Pacific Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 78
FIG NO. 35. Asia Pacific Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 80
FIG NO. 36. Asia Pacific Human Insulin Market for Indication 4, Revenue (USD Million) 2018 – 2032 82
FIG NO. 37. Asia Pacific Human Insulin Market for Indication 5, Revenue (USD Million) 2018 – 2032 84
FIG NO. 38. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 87
FIG NO. 39. Market Attractiveness Analysis, By Insulin 88
FIG NO. 40. Incremental Revenue Growth Opportunity by Insulin, 2024 – 2032 88
FIG NO. 41. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 89
FIG NO. 42. Asia Pacific Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 90
FIG NO. 43. Asia Pacific Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 92
FIG NO. 44. Asia Pacific Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 94
FIG NO. 45. Asia Pacific Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 96
FIG NO. 46. Asia Pacific Human Insulin Market for Insulin 5, Revenue (USD Million) 2018 – 2032 98
FIG NO. 47. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 101
FIG NO. 48. Market Attractiveness Analysis, By Technology 102
FIG NO. 49. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 102
FIG NO. 50. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 103
FIG NO. 51. Asia Pacific Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 104
FIG NO. 52. Asia Pacific Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 106
FIG NO. 53. Asia Pacific Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 108
FIG NO. 54. Asia Pacific Human Insulin Market for Technology 4, Revenue (USD Million) 2018 – 2032 110
FIG NO. 55. Asia Pacific Human Insulin Market for Technology 5, Revenue (USD Million) 2018 – 2032 112
FIG NO. 56. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 115
FIG NO. 57. Market Attractiveness Analysis, By Distribution Channel 116
FIG NO. 58. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 116
FIG NO. 59. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 117
FIG NO. 60. Asia Pacific Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 118
FIG NO. 61. Asia Pacific Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 120
FIG NO. 62. Asia Pacific Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 122
FIG NO. 63. Asia Pacific Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 124
FIG NO. 64. Asia Pacific Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 126
FIG NO. 65. Asia Pacific Human Insulin Market Revenue Share, By Region, 2023 & 2032 129
FIG NO. 66. Market Attractiveness Analysis, By Region 130
FIG NO. 67. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 130
FIG NO. 68. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 131
FIG NO. 69. North America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 138
FIG NO. 70. Europe Human Insulin Market Revenue, 2018 – 2032 (USD Million) 146
FIG NO. 71. Asia Pacific Human Insulin Market Revenue, 2018 – 2032 (USD Million) 154
FIG NO. 72. Latin America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 162
FIG NO. 73. Middle East Human Insulin Market Revenue, 2018 – 2032 (USD Million) 170
FIG NO. 74. Africa Human Insulin Market Revenue, 2018 – 2032 (USD Million) 178
FIG NO. 75. Research Methodology – Detailed View 189
FIG NO. 76. Research Methodology 190

List of Tables
TABLE NO. 1. : Asia Pacific Human Insulin Market: Snapshot 27
TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 31
TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 33
TABLE NO. 4. : Asia Pacific Human Insulin Market Revenue, By Region, 2018 – 2023 43
TABLE NO. 5. : Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 44
TABLE NO. 6. : Key Raw Materials & Suppliers 45
TABLE NO. 7. : Asia Pacific Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61
TABLE NO. 8. : Asia Pacific Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61
TABLE NO. 9. : Asia Pacific Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63
TABLE NO. 10. : Asia Pacific Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63
TABLE NO. 11. : Asia Pacific Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65
TABLE NO. 12. : Asia Pacific Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65
TABLE NO. 13. : Asia Pacific Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67
TABLE NO. 14. : Asia Pacific Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67
TABLE NO. 15. : Asia Pacific Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69
TABLE NO. 16. : Asia Pacific Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69
TABLE NO. 17. : Asia Pacific Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75
TABLE NO. 18. : Asia Pacific Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75
TABLE NO. 19. : Asia Pacific Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77
TABLE NO. 20. : Asia Pacific Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77
TABLE NO. 21. : Asia Pacific Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79
TABLE NO. 22. : Asia Pacific Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79
TABLE NO. 23. : Asia Pacific Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81
TABLE NO. 24. : Asia Pacific Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81
TABLE NO. 25. : Asia Pacific Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83
TABLE NO. 26. : Asia Pacific Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83
TABLE NO. 27. : Asia Pacific Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89
TABLE NO. 28. : Asia Pacific Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89
TABLE NO. 29. : Asia Pacific Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91
TABLE NO. 30. : Asia Pacific Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91
TABLE NO. 31. : Asia Pacific Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93
TABLE NO. 32. : Asia Pacific Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93
TABLE NO. 33. : Asia Pacific Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95
TABLE NO. 34. : Asia Pacific Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95
TABLE NO. 35. : Asia Pacific Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97
TABLE NO. 36. : Asia Pacific Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97
TABLE NO. 37. : Asia Pacific Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103
TABLE NO. 38. : Asia Pacific Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103
TABLE NO. 39. : Asia Pacific Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105
TABLE NO. 40. : Asia Pacific Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105
TABLE NO. 41. : Asia Pacific Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107
TABLE NO. 42. : Asia Pacific Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107
TABLE NO. 43. : Asia Pacific Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109
TABLE NO. 44. : Asia Pacific Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109
TABLE NO. 45. : Asia Pacific Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111
TABLE NO. 46. : Asia Pacific Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111
TABLE NO. 47. : Asia Pacific Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117
TABLE NO. 48. : Asia Pacific Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117
TABLE NO. 49. : Asia Pacific Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119
TABLE NO. 50. : Asia Pacific Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119
TABLE NO. 51. : Asia Pacific Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121
TABLE NO. 52. : Asia Pacific Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121
TABLE NO. 53. : Asia Pacific Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123
TABLE NO. 54. : Asia Pacific Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123
TABLE NO. 55. : Asia Pacific Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125
TABLE NO. 56. : Asia Pacific Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125
TABLE NO. 57. : Asia Pacific Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130
TABLE NO. 58. : Asia Pacific Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130
TABLE NO. 59. : Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131
TABLE NO. 60. : Asia Pacific Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131
TABLE NO. 61. : Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132
TABLE NO. 62. : Asia Pacific Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132
TABLE NO. 63. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133
TABLE NO. 64. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133
TABLE NO. 65. : Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134
TABLE NO. 66. : Asia Pacific Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134
TABLE NO. 67. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135
TABLE NO. 68. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135
TABLE NO. 69. : North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137
TABLE NO. 70. : North America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 137
TABLE NO. 71. : North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138
TABLE NO. 72. : North America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 138
TABLE NO. 73. : North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139
TABLE NO. 74. : North America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 139
TABLE NO. 75. : North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140
TABLE NO. 76. : North America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 140
TABLE NO. 77. : North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141
TABLE NO. 78. : North America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 141
TABLE NO. 79. : North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142
TABLE NO. 80. : North America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 142
TABLE NO. 81. : Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145
TABLE NO. 82. : Europe Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 145
TABLE NO. 83. : Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146
TABLE NO. 84. : Europe Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 146
TABLE NO. 85. : Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147
TABLE NO. 86. : Europe Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 147
TABLE NO. 87. : Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148
TABLE NO. 88. : Europe Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 148
TABLE NO. 89. : Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149
TABLE NO. 90. : Europe Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 149
TABLE NO. 91. : Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150
TABLE NO. 92. : Europe Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 150
TABLE NO. 93. : Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153
TABLE NO. 94. : Asia Pacific Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 153
TABLE NO. 95. : Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154
TABLE NO. 96. : Asia Pacific Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 154
TABLE NO. 97. : Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155
TABLE NO. 98. : Asia Pacific Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 155
TABLE NO. 99. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156
TABLE NO. 100. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 156
TABLE NO. 101. : Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157
TABLE NO. 102. : Asia Pacific Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 157
TABLE NO. 103. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158
TABLE NO. 104. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 158
TABLE NO. 105. : Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161
TABLE NO. 106. : Latin America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 161
TABLE NO. 107. : Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162
TABLE NO. 108. : Latin America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 162
TABLE NO. 109. : Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163
TABLE NO. 110. : Latin America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 163
TABLE NO. 111. : Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164
TABLE NO. 112. : Latin America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 164
TABLE NO. 113. : Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165
TABLE NO. 114. : Latin America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 165
TABLE NO. 115. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166
TABLE NO. 116. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 166
TABLE NO. 117. : Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169
TABLE NO. 118. : Middle East Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 169
TABLE NO. 119. : Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170
TABLE NO. 120. : Middle East Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 170
TABLE NO. 121. : Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171
TABLE NO. 122. : Middle East Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 171
TABLE NO. 123. : Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172
TABLE NO. 124. : Middle East Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 172
TABLE NO. 125. : Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173
TABLE NO. 126. : Middle East Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 173
TABLE NO. 127. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174
TABLE NO. 128. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 174
TABLE NO. 129. : Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177
TABLE NO. 130. : Africa Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 177
TABLE NO. 131. : Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178
TABLE NO. 132. : Africa Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 178
TABLE NO. 133. : Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179
TABLE NO. 134. : Africa Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 179
TABLE NO. 135. : Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180
TABLE NO. 136. : Africa Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 180
TABLE NO. 137. : Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181
TABLE NO. 138. : Africa Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 181
TABLE NO. 139. : Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182
TABLE NO. 140. : Africa Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 182

Frequently Asked Questions:

What is the current size of the Asia Pacific Human Insulin?

The Asia Pacific Human Insulin market was valued at USD 6,171.90 million in 2023 and is expected to reach USD 10,169.13 million by 2032.

What factors are driving the growth of the Asia Pacific Human Insulin?

Rising diabetes prevalence, aging population, government initiatives, and advancements in insulin delivery technologies are key growth drivers.

What are the key segments within the Asia Pacific Human Insulin?

The market is segmented by device (pens, syringes), indication (type 1, type 2, gestational diabetes), insulin type, distribution channel, and geography.

What are some challenges faced by the Asia Pacific Human Insulin?

High therapy costs, limited rural access, regulatory complexities, and supply chain disruptions remain major challenges.

Who are the major players in the Asia Pacific Human Insulin?

Key players include Novo Nordisk, Eli Lilly, Pfizer, Biocon, Wockhardt, Lupin, and Tonghua Dongbao Pharmaceutical.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –